RxDoctor Payments Data

Timmothy Reece, MD

Family Medicine · White Hall, ARNPI 1679794762

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 85 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$220
  • AbbVie$129
  • Pfizer$118
  • Amgen$78
  • AstraZeneca$72
  • Novo Nordisk$68
  • plus $561 from 17 others

What the payments were for

  • Food & beverage$1,18095%
  • Education$655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,245 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$698,241
Medicare patients
1,054
Services billed
45,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide238$253,023
EliquisApixaban277$224,390
MounjaroTirzepatide158$174,258
JardianceEmpagliflozin164$150,826
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog73$77,984
JanuviaSitagliptin Phosphate71$74,005
LinzessLinaclotide91$64,576
EntrestoSacubitril/Valsartan57$53,090
JanumetSitagliptin Phos/Metformin Hcl59$48,550
Tresiba Flextouch U-200Insulin Degludec21$34,006
XareltoRivaroxaban49$32,452
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$30,152
Lantus SolostarInsulin Glargine,hum.Rec.Anlog122$23,670
TradjentaLinagliptin30$23,271
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog60$23,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$68$253,023238 claims
PfizerEliquis$118$224,390277 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$11$180,042205 claims
MerckJanuvia, Janumet, Belsomra, Janumet Xr$220$139,935163 claims
AbbVieLinzess$129$64,57691 claims
NovartisEntresto$46$53,09057 claims
GSKTrelegy Ellipta, Breo Ellipta$28$41,88476 claims
AstraZenecaFarxiga, Symbicort$72$38,41088 claims
Johnson & JohnsonXarelto$16$32,45249 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$8,57618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in White Hall

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →